SK Chem Strikes Korea Sanofi Vaccine Deal
This article was originally published in PharmAsia News
Executive Summary
In an ongoing effort to boost its vaccine portfolio, SK Chemicals has reached a strategic alliance with Sanofi Pasteur, the vaccine division of Sanofi, to begin marketing in South Korea Sanofi's Menactra, a meningococcal conjugate vaccine, and a live-attenuated Japanese encephalitis vaccine.
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.